Premium
Two‐year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series
Author(s) -
Yilmaz Neslihan,
Can Meryem,
Kocakaya Derya,
Karakurt Sait,
Yavuz Sule
Publication year - 2014
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.12399
Subject(s) - medicine , dlco , pulmonary function testing , interstitial lung disease , diffusing capacity , scleroderma (fungus) , mycophenolate , vital capacity , lung , cyclophosphamide , high resolution computed tomography , mycophenolic acid , radiology , gastroenterology , surgery , lung function , transplantation , pathology , chemotherapy , inoculation
To assess the effect of mycophenolate mofetil ( MMF ) on pulmonary functions in patients with systemic sclerosis‐associated lung disease ( SS c‐ ILD ) who experienced an inadequate response to first line cyclophosphamide ( CYC ) therapy. Twelve consecutive SS c‐ ILD patients who received MMF due to inadequate response to CYC as a first line agent, were retrospectively reviewed. Over the course of 2 years, pulmonary function tests ( PFT ) and high‐resolution computed tomography ( HRCT ) scans were performed. Following initial baseline tests, PFT s were continued at a frequency of every 6 months and HRCT scans were performed every 12 months. After MMF treatment, values of forced vital capacity ( FVC ) and diffusing capacity for carbon monoxide ( DLCO ) improved in three (25%) and two (16.6%) patients, respectively. It is also noted that the evaluation of serial HCRT scans showed no change in 54.5% of patients. Our case series suggested that PFT and imaging scores seemed to be stabilized by MMF in SS c‐ ILD patients who were inadequate responders to CYC .